Literature DB >> 28265853

Response-Derived Input Function Estimation for Dynamic Contrast-Enhanced MRI Demonstrated by Anti-DLL4 Treatment in a Murine U87 Xenograft Model.

Matthew D Silva1, Brittany Yerby2, Jodi Moriguchi3, Albert Gomez4, H Toni Jun3, Angela Coxon3, Sharon E Ungersma2.   

Abstract

PURPOSE: Dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) is an accepted method to evaluate tumor perfusion and permeability and anti-vascular cancer therapies. However, there is no consensus on the vascular input function estimation method, which is critical to kinetic modeling and K trans estimation. This work proposes a response-derived input function (RDIF) estimated from the response of the tumor, modeled as a linear, time-invariant (LTI) system. PROCEDURES: In an LTI system, an unknown input can be estimated from the system response. If applied to DCE MRI, this method would eliminate need of distal image-derived inputs, model inputs, or reference regions. The RDIF method first determines each tumor pixel's best-fit input function, and then combines the individual fits into a single input function for the entire tumor. The method was tested with simulations and a xenograft study with anti-vascular drug treatment.
RESULTS: Simulations showed successful estimation of input function expected values and good performance in the presence of noise. In vivo, significant reductions in K trans and AUC occurred 2 days following anti-delta-like ligand 4 treatment. The in vivo study results yielded K trans consistent with published data in xenograft models.
CONCLUSION: The RDIF method for DCE analysis offers an alternative, easy-to-implement method for estimating the input function in tumors. The method assumes that during the DCE experiment, the changes observed by MRI result solely from vascular perfusion and permeability kinetics, and that information can be used to model the input function. Importantly, the method is demonstrated in a murine xenograft study to yield K trans results consistent with literature values and suitable for compound studies.

Entities:  

Keywords:  DLL4; Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI); Input function; K trans

Mesh:

Substances:

Year:  2017        PMID: 28265853     DOI: 10.1007/s11307-017-1065-y

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  31 in total

Review 1.  Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies.

Authors:  James P B O'Connor; Alan Jackson; Geoff J M Parker; Caleb Roberts; Gordon C Jayson
Journal:  Nat Rev Clin Oncol       Date:  2012-02-14       Impact factor: 66.675

2.  Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model.

Authors:  Thomas E Yankeelov; Jeffrey J Luci; Martin Lepage; Rui Li; Laura Debusk; P Charles Lin; Ronald R Price; John C Gore
Journal:  Magn Reson Imaging       Date:  2005-05       Impact factor: 2.546

Review 3.  Modeling tracer kinetics in dynamic Gd-DTPA MR imaging.

Authors:  P S Tofts
Journal:  J Magn Reson Imaging       Date:  1997 Jan-Feb       Impact factor: 4.813

4.  A model-constrained Monte Carlo method for blind arterial input function estimation in dynamic contrast-enhanced MRI: I. Simulations.

Authors:  Matthias C Schabel; Jacob U Fluckiger; Edward V R DiBella
Journal:  Phys Med Biol       Date:  2010-08-03       Impact factor: 3.609

Review 5.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

6.  In vitro study of relationship between signal intensity and gadolinium-DTPA concentration at high magnetic field strength.

Authors:  D Shahbazi-Gahrouei; M Williams; B J Allen
Journal:  Australas Radiol       Date:  2001-08

Review 7.  The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth.

Authors:  Gavin Thurston; Irene Noguera-Troise; George D Yancopoulos
Journal:  Nat Rev Cancer       Date:  2007-05       Impact factor: 60.716

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 9.  Biomarkers of response and resistance to antiangiogenic therapy.

Authors:  Rakesh K Jain; Dan G Duda; Christopher G Willett; Dushyant V Sahani; Andrew X Zhu; Jay S Loeffler; Tracy T Batchelor; A Gregory Sorensen
Journal:  Nat Rev Clin Oncol       Date:  2009-06       Impact factor: 66.675

Review 10.  DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.

Authors:  J P B O'Connor; A Jackson; G J M Parker; G C Jayson
Journal:  Br J Cancer       Date:  2007-01-09       Impact factor: 7.640

View more
  1 in total

1.  Comparative study of preclinical mouse models of high-grade glioma for nanomedicine research: the importance of reproducing blood-brain barrier heterogeneity.

Authors:  Caterina Brighi; Lee Reid; Laura A Genovesi; Marija Kojic; Amanda Millar; Zara Bruce; Alison L White; Bryan W Day; Stephen Rose; Andrew K Whittaker; Simon Puttick
Journal:  Theranostics       Date:  2020-05-15       Impact factor: 11.556

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.